INTERLEUKIN INHIBITORS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Interleukin Inhibitors Market Size and Trends

The global interleukin inhibitors market is estimated to be valued at USD 32.60 Bn in 2024 and is expected to reach USD 74.81 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031. Interleukin inhibitors function by blocking specific interleukins that play a role in causing inflammation. Their use in treatment of diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease is expected to drive demand.

Discover market dynamics shaping the industry: Request sample copy

The market is witnessing positive growth primarily due to factors such as rising prevalence of immune mediated inflammatory diseases, growing geriatric population susceptible to such conditions, and increasing approval and launches of novel interleukin inhibitors.

Discover high revenue pocket segments and roadmap to it: Request sample copy

Insights By Type - IL-1 inhibitors continue to lead the market on effectiveness against inflammatory conditions

In terms of type, IL-1 inhibitors segment is expected to contribute the highest share of the market with 32.1% in 2024 owing to their proven effectiveness against various inflammatory conditions. IL-1 inhibitors work by blocking the activity of interleukin-1 (IL-1), a pro-inflammatory cytokine that plays a key role in inflammation. Blocking IL-1 can provide relief from inflammation-driven symptoms for diseases like rheumatoid arthritis and inflammatory bowel disease. Clinical studies like ILARIS (Canakinumab) in rheumatoid arthritis patients have consistently shown IL-1 inhibitors to significantly reduce pain, swelling, and other symptoms for patients suffering from these chronic conditions.

Insights By Route of Administration - Oral administration gains prominence through improved compliance

In terms of route of administration, oral is expected to contribute the highest share of the market with 32.1% in 2024. The oral route provides distinct advantages over other forms of administration like injections. Oral drugs empower patients to self-administer treatment at home, without needing to visit clinicians for each dose. This significantly improves patient compliance to prescribed treatment regimens. Missing doses can reduce the effectiveness of medications, so reliable daily intake is important.

Insights By Application - Rheumatoid arthritis drives segment growth due to its prevalence and treatment costs

In terms of application, rheumatoid arthritis is expected to contribute the highest share of the market with 30.1% in 2024. According to the WHO, in June 2023, rheumatoid arthritis is the most common type of autoimmune arthritis, affecting over 54.4 million people worldwide. Persistent inflammation arising from autoimmune responses in the joints causes stiffness, pain, and loss of function for sufferers. Without treatment, rheumatoid arthritis can seriously damage joints, bones, and organs. Its socioeconomic impact comes from both direct treatment costs and lost productivity.

Regional Insights

To learn more about this report, Request sample copy

Dominating Region: North America

North America dominates the interleukin inhibitors market with an estimated share of 36.2% in 2024. This can be attributed to robust research and development activities by major pharmaceutical companies in the region. The presence of advanced healthcare infrastructure and favorable reimbursement policies have also contributed to market growth.

Fastest-Growing Region: Asia Pacific

The Asia Pacific market exhibits the fastest growth fueled by rising healthcare expenditure and high disease prevalence. Focus of international players to tap into the region's huge patient pool and market potential is also expected to drive the regional market growth.

Interleukin Inhibitors Market Outlook for Key Countries

U.S. Dominates due to High Prevalence of Autoimmune Diseases

The U.S. is a leader in the interleukin inhibitors market, driven by a high prevalence of autoimmune diseases such as rheumatoid arthritis and psoriasis. In February 2023, the American College of Rheumatology reported that approximately 1.3 million people in the U.S. have rheumatoid arthritis, which underscores the demand for effective treatments like interleukin inhibitors. The country has a well-established healthcare infrastructure that supports extensive R&D initiatives, with major pharmaceutical companies actively developing new therapies.

Growing Healthcare Investments in Canada

Canada plays a significant role in driving growth in the global interleukin inhibitors market, particularly in the context of treating asthma and other autoimmune diseases. For instance, according to the Canadian Pediatric Society's November 2021 report, asthma affects approximately 10% of Canadians overall, with its prevalence rising to 20% among children and adolescents, including indigenous communities. Asthma exacerbations are a leading cause of emergency room visits, hospital admissions, and school absences in children.

Advancements in Biologics and Personalized Medicine in Japan

The Japan interleukin inhibitors market is characterized by a focus on advanced biologics and personalized medicine. The country has a robust healthcare system that supports the development and adoption of innovative therapies. On December 27, 2023, BIMZELX (bimekizumab) received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) in adults who have not responded adequately to existing treatments.

China: Government Investments and Biopharmaceutical Advancements

The China interleukin inhibitors market is experiencing rapid growth due to significant government investments aimed at improving healthcare access and treatment options for autoimmune diseases. The Chinese government is actively promoting research and development in biopharmaceuticals, For instance, in 2023, the Chinese government allocated over USD 8.5 billion in its National Healthcare Security Fund to improve access to innovative drugs and treatments, including biologics for autoimmune diseases like rheumatoid arthritis and psoriasis.

Emerging Market Potential in India

The market for interleukin inhibitors in India is expanding rapidly as awareness about autoimmune diseases increases among healthcare providers and patients. The increasing prevalence of autoimmune diseases propels market growth as more patients seek effective therapeutic options. Government initiatives like Ayushman Bharat Scheme aimed at enhancing healthcare delivery systems further support the adoption of interleukin inhibitors across various cities like Delhi, Mumbai, Bengaluru.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Request sample copy

Top Strategies Followed by Global Interleukin Inhibitors Market Players

• Established Players: Leading pharmaceutical companies in the interleukin inhibitors market are heavily investing in research and development (R&D) to innovate and improve their offerings. For example, Novartis, a major player in the interleukin inhibitors market, continues to invest in R&D to expand its portfolio of immunotherapies. In July 2024, Novartis announced a US$ 2.4 billion investment in R&D, aimed at advancing treatments for autoimmune diseases, including interleukin inhibitors such as Cosentyx (secukinumab), which targets IL-17A.
• Mid-Level Players: Mid-sized players, such as Haplogen AB, have formed collaborations to enhance their production capabilities. In March 2024, Haplogen entered a strategic collaboration with CureTech to expand its interleukin inhibitors portfolio targeting autoimmune diseases. These collaborations help mid-level players boost their market presence and capabilities.
• Small-Scale Players: Smaller companies often target niche markets with specialized or innovative products. Trillium Therapeutics, a biotech startup, focuses on developing targeted therapies for inflammatory diseases. Its research into interleukin inhibitors as part of TLR-9 agonists, announced in April 2024, highlights how smaller players cater to specific therapeutic needs in underserved segments.

Emerging Startups in the Global Interleukin Inhibitors Market

Innovative Technologies: Startups are developing advanced technologies such as AI and machine learning to optimize interleukin inhibitors' effectiveness. Proximagen, a startup focused on immunotherapy, announced in February 2024 that it was developing an AI-based platform to predict optimal dosages for interleukin inhibitors in patients with autoimmune disorders, aiming to improve personalized treatment.

Sustainable Solutions: A growing number of startups are focusing on sustainability in the development of interleukin inhibitors. For instance, BioNaturals, a biotech company based in Sweden, is developing eco-friendly production methods for its interleukin inhibitors. In July 2024, the company announced its commitment to reducing carbon emissions by 40% in the next five years through the use of renewable energy in its production facilities.

Market Contribution: Startups are also forming strategic partnerships to accelerate innovation. Cellnovo Biotech, a U.K.-based startup, partnered with Pfizer in April 2024 to co-develop a new interleukin inhibitor for psoriasis. This collaboration is expected to provide both companies with the resources to bring the product to market more quickly, benefiting patients with limited treatment options.

Interleukin Inhibitors Industry News

• In September 2024, Eli Lilly, a pharmaceutical company’s lebrikizumab-based drug, EBGLYSS, was granted U.S. FDA approval for adults and children aged 12 and older with moderate-to-severe atopic dermatitis that is inadequately controlled by topical treatments. This new treatment provides significant symptom relief for patients, offering a promising option in the management of this chronic skin condition.
• In August 2024, Regeneron Pharmaceuticals, a biopharmaceutical company, presented 20 abstracts at the ERS Congress, showcasing important advancements in the treatment of respiratory diseases such as COPD, asthma, and chronic rhinosinusitis with nasal polyps. The abstracts focused on Dupixent and itepekimab, highlighting their potential to transform care in these challenging conditions.
• In June 2024, Johnson & Johnson, a global healthcare company, announced successful Phase 3 results from the GRAVITI study for TREMFYA (guselkumab). This study demonstrated that TREMFYA is the only IL-23 inhibitor with both subcutaneous and intravenous induction options, enhancing its potential as a versatile treatment for autoimmune diseases.
• In May 2024, AbbVie, a biopharmaceutical company, presented 15 abstracts at Digestive Disease Week, unveiling new data supporting its gastroenterology portfolio. The abstracts focused particularly on risankizumab and upadacitinib as key therapies for treating inflammatory bowel diseases (IBDs), reinforcing AbbVie’s leadership in this space.
• In May 2024, AstraZeneca, a global pharmaceutical company, showcased its innovations in respiratory diseases at ATS 2024, with a special emphasis on IL inhibitors like tezepelumab and tozorakimab for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and eosinophilic granulomatosis with polyangiitis (EGPA). These data highlighted AstraZeneca’s ongoing commitment to advancing treatments in respiratory care.

Key Takeaways from Analyst

• The global interleukin inhibitors market is expected to grow due to the rising prevalence of immune diseases like rheumatoid arthritis and psoriasis. Advancements in monoclonal antibody therapy have made interleukin inhibitors first-line treatments. North America leads the market, but Asia Pacific is set for rapid growth due to increased disease prevalence and better access to treatments.
• Challenges include price sensitivity in generics, potential biosimilars, regulatory hurdles, and risks from patent cliffs. Future growth depends on developing new interleukin-targeting therapies and expanding into underserved autoimmune disorders. Strategic partnerships in emerging markets will also drive market penetration.

Market Report Scope

Market Dynamics

Market Driver - Increasing prevalence of autoimmune diseases

The global burden of autoimmune diseases has been rising significantly over the past few decades. Various factors like changing lifestyle patterns, environmental pollutants, and genetic susceptibility have all contributed to this upward trend. For instance, in September 2024, the U.S. Food and Drug Administration (FDA) approved bimekizumab (Bimzelx) for the treatment of four chronic immune-mediated inflammatory diseases, psoriatic arthritis, nonradiographic, and axial spondyloarthritis. This approval expands treatment options in response to the increasing prevalence of autoimmune diseases and the growing demand for targeted therapies.

Market Challenge - High cost of treatment

One of the key challenges for the global interleukin inhibitors market is the high cost of treatment. Interleukin inhibitors are biologic drugs used for the treatment of various chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Developing biologic drugs requires huge investments in R&D and involves complex manufacturing processes. This makes these drugs extremely expensive for patients. A typical course of treatment using interleukin inhibitors can cost anywhere between US$ 20,000 and US$ 50,000 per year.

Market Opportunity - Advancements in Biologic Therapies

One of the key opportunities for the global interleukin inhibitors market lies in ongoing advancements in biologic therapies. Continuous research and development are expanding the therapeutic applications of interleukin inhibitors. New disease indications such as non-infectious uveitis and Behcet's disease are being explored. Second and third generation interleukin inhibitors with improved formulations, dosing schedules and delivery methods are also being developed. For example, newer subcutaneous and inhaled formulations reduce administration hassles.

Key Stakeholders of Market

What does Growth in the Interleukin Inhibitors market mean for Different Stakeholders?

The interleukin inhibitors industry has multiple players with varied designations and offers multiple opportunities based on their scope of operations.

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Market Segmentation

• By Type Insights (Revenue, USD Bn, 2019 - 2031)
• • IL-1 inhibitors
  • IL-5 inhibitors
  • IL-6 inhibitors
  • IL-17 inhibitors
  • IL-23 inhibitors
  • Other types
• By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
• • Oral
  • Subcutaneous (SC)
  • Intravenous (IV)
  • Others
• By Application Insights (Revenue, USD Bn, 2019 - 2031)
• • Rheumatoid arthritis
  • Psoriatic arthritis
  • Psoriasis
  • Inflammatory bowel disease (IBD)
  • Asthma
  • Multiple Sclerosis
  • Ulcerative colitis
  • Crohn’s disease
  • Other applications
• By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
• • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
• • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
• • AbbVie Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • Novartis AG
  • Sanofi S.A.
  • GSK plc
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited
  • Biogen Inc.
  • UCB S.A.
  • Astellas Pharma Inc.
  • Bayer AG
  • Sandoz International GmbH